Regenerex Pharma is a small, early-stage wound care company developing and commercializing products to treat chronic and acute wounds, including diabetic ulcers, pressure ulcers, venous ulcers, burns, and surgical wounds. The company's core technology is QBx™, a proprietary active ingredient derived from oak bark extract that Regenerex claims works by down-regulating enzymes (proteases and MMPs) that, when elevated, impede wound healing. Regenerex currently markets two products: Xcellderma™, an OTC sterile liquid bandage for minor wounds, and Accelerex™, a sterile wound cream classified as a medical device that contains QBx™ and targets more serious chronic and acute wounds. The company sells to healthcare providers including home health providers, nursing homes, wound care clinics, and hospitals. Regenerex is also pursuing managed care agreements with state Medicaid programs, the VA, Medicare, and correctional facilities, under which it would provide its full Wound Closure System — products, clinical protocols, and software — on a contract basis. Internationally, Regenerex is pursuing distribution partnerships in the Middle East and Asia. The business model is largely aspirational at this stage; Regenerex has FDA clearance for Xcellderma™ but is still pursuing FDA re-certification for broader drug and medical device manufacturing. The company manufactures through a leased facility in Tennessee using an asset-light model.